



REVIEW ARTICLE

Staphylococcal Cassette Chromosome *mec* (SCC*mec*) in coagulase negative staphylococci

A. Martínez-Meléndez^a, R. Morfín-Otero^b, L. Villarreal-Treviño^a,
G. González-González^c, J. Llaca-Díaz^d, E. Rodríguez-Noriega^b,
A. Camacho-Ortíz^e, E. Garza-González^{d,f,*}



CrossMark

^a Departamento de Microbiología e Inmunología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico

^b Hospital Civil de Guadalajara "Fray Antonio Alcalde" e Instituto de Patología Infectosa y Experimental, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico

^c Departamento de Microbiología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Mexico

^d Departamento de Patología Clínica, Hospital Universitario "Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo León, Monterrey, Mexico

^e Servicio de Infectología, Hospital Universitario "Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo León, Monterrey, Mexico

^f Servicio de Gastroenterología, Hospital Universitario "Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo León, Monterrey, Mexico

Received 17 June 2015; accepted 9 October 2015

Available online 20 April 2016

KEYWORDS

Methicillin resistance;
Bacterial drug
resistance;
Bacteremia

Abstract Coagulase-negative staphylococci (CoNS) are among the main causative agents of bacteremia. *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* are the CoNS species most frequently isolated. These species are often associated with infections in immunocompromised patients who have a medical device implant. Methicillin resistance was first described in *Staphylococcus aureus*; it has also been reported in CoNS species. Methicillin resistance is conferred by expression of the *mecA* gene, contained within the staphylococcal cassette chromosome (SCC*mec*). *mecA* gene codes for the PBP2a protein which shows poor binding to beta-lactam antibiotics, so methicillin-resistant strains are resistant to beta-lactams. The presence of SCC*mec* in CoNS species complicates infections caused by these organisms, since it confers resistance to a variety of antibiotics, making treatment difficult. This review analyzes the clinical relevance of SCC*mec* as well as the diversity and structure of elements present in CoNS species.

© 2016 Universidad Autónoma de Nuevo León. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author at: Servicio de Gastroenterología y Departamento de Patología Clínica, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Avenida Francisco I. Madero S/N, Colonia Mitras Centro, CP 64460 Monterrey, NL, Mexico. Tel.: +52 81 83 33 36 64/89 11 11x3317; fax: +52 81 83 29 41 66.

E-mail address: elvira_garza_gzz@yahoo.com (E. Garza-González).

<http://dx.doi.org/10.1016/j.rmu.2015.10.003>

1665-5796/© 2016 Universidad Autónoma de Nuevo León. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Coagulase-negative staphylococci (CoNS) are key agents contributing to infections in hospital environments. They are microorganisms which form part of the normal skin and mucus membranes of humans, frequently isolated from patients with skin alterations, for instance, subjects undergoing surgery or with trauma injuries. Even though they are sometimes considered as culture pollutants in clinical bacteriology laboratories, they are currently considered opportunist pathogens. They have also been isolated from patients with implanted devices, such as catheters, prosthesis, derivations, etc.¹⁻³

In our hospital, studies on the frequency of isolated microorganisms in medical device-related infections have been conducted before. An example of which is a study of the incidence of infections related to central venous catheters (CVC) in the intensive care unit (ICU), where a group of CoNS was the second most frequent group (8.8%) in this type of infection, only exceeded by *Staphylococcus aureus*.⁴ Similarly, in a study of infectious endocarditis cases, CoNS were the most frequent causative agent after *S. aureus*.⁵

In diverse studies, CoNS have been classified as the main causative agent of bacteremia, causing around 30% of bacteremia cases confirmed by the laboratory.⁶ Within this group, *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* are two CoNS species most frequently isolated in bacteriology laboratories.⁷ These agents are the most frequent cause of bacteremia. Also, these species present high percentages of resistance to methicillin, a characteristic which converts infections produced by these species into difficult-to-treat pathologies.⁸ In this revision, we will discuss the clinical relevance of CoNS, as well as the genetic elements responsible for methicillin resistance of CoNS, particularly *S. epidermidis* and *S. haemolyticus*.

Resistance to methicillin

Originally, penicillin was the pharmaceutical of choice for the treatment of infections caused by *S. aureus*. Soon after, penicillin-resistant strains emerged due to the acquisition of plasmids which codify β-lactamases or penicillinases.

Methicillin was introduced in 1960: a semisynthetic penicillin resistant to penicillinases. Nevertheless, a year later the first methicillin-resistant strains appeared. Consequently, the term methicillin-resistant *S. aureus* was coined (MRSA). MRSA strains present an additional resistance to the other β-lactamases antibiotics, including cephalosporins and cephemic agents.⁹

Resistance to methicillin has also been reported in CoNS species isolated from clinical samples, with proportions even higher than those reported in *S. aureus*. There are reports of methicillin-resistant *S. epidermidis* strains (MRSE) and methicillin-resistant *S. haemolyticus* (MRSH), isolated from blood, with resistance percentages over 70% for both species.¹⁰⁻¹² Also, MRSE and MRSH have been isolated from healthy subjects, who are colonized, thus constituting an important dissemination source for these species.^{13,14}

Table 1 Structure of the classes of *mec* complex.

Class complex <i>mec</i>	Structure
A	<i>mecl-mecR1-mecA-IS431</i>
B	<i>IS1272-ΔmecR1-mecA-IS431</i>
C	<i>IS431-ΔmecR1-mecA-IS431</i>
D	<i>ΔmecR1-mecA-IS431</i>
E	<i>ΔmecR1-mecA-IS431</i>

Mechanism of resistance to β-lactams antibiotics in methicillin-resistant strains

Penicillin binding proteins (PBP) are proteins involved in the metabolism of peptidoglycan of the bacterial cell wall.¹⁵ When β-lactam antibiotics enter the active PBP site they are bound covalently, inhibiting PBP function, hence the wall synthesis.¹⁶

Methicillin-resistant strains produce a penicillin-binding protein, known as PBP2a or PBP2' which presents a low affinity to β-lactams.^{16,17} Therefore, antibiotics do not remain attached to PBP2a, inhibition of the peptidoglycan synthesis does not occur, and cellular lysis is avoided.¹⁶

PBP2a protein is coded by the *mecA* gene, which is contained in a mobile genetic element called staphylococcal cassette chromosome *mec* (SCC*mec*).¹⁸ SCC*mec* was first described in an MRSA strain, whose sequencing set the bases for the study of SCC*mec* basic characteristics, as well as its diversity.

SCC*mec* characteristics

SCC*mec* is a mobile genetic element which attaches in the *bacterial chromosomal attachment site (attBSC)*, near the origin of replication in staphylococci. Moreover, SCC*mec* possesses insertion sequences (IS) which flank the *mecA* gene, as well as expression-regulator genes. The set of regulator regions, insertion sequences and *mecA* gene, are called a *mec* complex. Several types of *mec* complexes have been described, depending on the IS type present in the *mecA* environment. So far, five types of *mec* for *S. aureus* (complex A to E) have been described.¹⁹ *mec* complex is formed by *mecA*, regulator genes *mecl* and *mecR1*, as well as different insertion sequences which may partially delete regulator genes.

Class A *mec* complex is the prototype complex (Table 1); it contains the gene *mecA* and gene regulators *mecl* and *mecR1*. In class B *mec* complex, the gene *mecR1* is partially deleted by the insertion of IS1272; while in class C *mec* complex the gene *mecR1* is partially deleted by the insertion of IS431. Class C *mec* complex is divided into two variants, C1 and C2, depending on the orientation of IS431. Class D *mec* complex presents the gene *mecR1* deleted, but without an associated insertion sequence. Class E *mec* complex is similar to the latter, but with a greater rate of *mecR1* deletion.^{19,20} All complexes present an IS431 subsequent to *mecA*.

Also, SCC*mec* possesses genes which codify for recombinases. These recombinases are in charge of integrating the SCC*mec* in the bacterial chromosome. The recombinase gene groups are called *ccr*. There have been three different

Table 2 Types of *ccr* complexes.

Type of <i>ccr</i> complex	Allotype of <i>ccr</i> genes
Type 1	A1B1
Type 2	A2B2
Type 3	A3B3
Type 4	A4B4
Type 5	C1
Type 6	A5B3
Type 7	A1B6
Type 8	A1B3

Table 3 Types of SCCmec described for *S. aureus*.

Type of SCCmec	Type of <i>ccr</i> complex	Class of <i>mec</i> complex
I	1	B
II	2	A
III	3	A
IV	2	B
V	5	C2
VI	4	B
VII	5	C1
VIII	4	A
IX	1	C2
X	7	C1
XI	8	E

types of recombinases to date: *ccrA*, *ccrB*, and *ccrC*; coded by the genes *ccrA*, *ccrB* and *ccrC*, respectively. There are different allotypes for each one, depending on the existent homology degree.²¹ Various allotypes have been identified for recombinase A and B, while just one allotype has been described for recombinase C.²⁰ They have been classified into eight different types of complex *ccr* depending on existing recombinases and allotypes in the different cassettes (Table 2).

The regions located between the complex *ccr*, complex *mec* and SCCmec ends are known as J regions (joining regions), containing additional structures such as plasmids or IS, which have the ability to provide additional resistance characteristics.²⁰ The J1 region is located between the right chromosomal binding and the *ccr* complex. The J2 region is located between the *ccr* complex and the *mec* complex. The J3 region is located between the right chromosomal binding and the *mec* complex.

SCCmecs are classified into types and subtypes. SCCmec types are defined by the type of *mec* complex and *ccr* complex present. Subtypes are based on differences present in J regions (joining regions) within a SCCmec. These differences may be plasmids, insertion sequences, or pseudogenes.¹⁹ Thus far, eleven types of SCCmec in *S. aureus* have been described, based on the combination in *mec* complex class and *ccr* complex type (Table 3).^{21–25}

SCCmec and resistance to antibiotics

Different genetic elements, such as genomic islands, bacteriophages, pathogenicity islands, chromosomal cassettes,

plasmids, insertion sequences and transposons, intervene in the dissemination of resistance genes and staphylococci virulence.

Insertion sequences are particularly capable of carrying resistance determinants through homologous recombination. CoNS-resistant strains can function as a deposit for antibiotic-resistant genes, which may be transferred to microorganisms, including the *S. aureus* strains.²⁶

With the exception of *mecA*, type I, IV, V, VI and VII, SCCmec do not contain antibiotic-resistant genes. However, type II SCCmec bears the Tn554 transposon, which contains erythromycin-resistant genes (*ermA*) and spectinomycin (*spc*). This SCCmec also contains plasmid pUB110 (flanked by a pair of IS431 elements) which codifies resistance to kanamycin, tobramycin and bleomycin.

Similarly, type III SCCmec contains transposon Tn554, plasmid pUB110 (with the resistance determinants previously mentioned), an integrated copy of pT181 (confers resistance to tetracycline) and pI258 (resistance to mercury).²⁷ Type IX and X SCCmec contain determinants resistant to cadmium, copper and arsenate. Type XI SCCmec bears resistance to arsenate.

SCCmec in CoNS

In addition to the types and subtypes of SCCmec, there are variations of SCCmec and non-typeable SCCmec observed in several studies, mainly in CoNS, which means that CoNS have a wide reservoir of SCCmec structures. In the case of an SCCmec with a non-typeable *ccr* complex, there have been reports of *mec* complexes existing even in the absence of the known types of *ccr*.^{28,29} Moreover, the existence of new versions of recombinases has been suggested, hence it is not possible to detect them with the methodology established for *S. aureus*.

mec and *ccr* complexes go through complex recombining and reordering processes in CoNS genomes, through which the generation of new SCCmec types occurs. Most likely just a small fraction of the SCCmec diversity is present in *S. aureus*.

SCCmec IV is the most dominant in MRSA infections acquired in the community (CA-MRSA).³⁰ However, SCCmec IV is also frequently found in CoNS, particularly in *S. epidermidis*, in studies of the community and hospital environment. In a report on hospital isolations of *S. epidermidis*, 36% was type IV SCCmec, 34% type II SCCmec, 28% type III SCCmec and just 2% type I SCCmec.³¹ Another study conducted in healthy patients found a frequency of 57% of type IV SCCmec.¹⁴ Additionally, other types of SCCmec in *S. epidermidis* have often been reported. Such is the case of type III SCCmec which has been reported in clinical and community isolations.^{31,32}

Some studies suggest the transference of SCCmec between *S. epidermidis* and *S. aureus*.³¹ Type IV SCCmec in *S. epidermidis* shows a homology of 98–99% with type IV SCCmec in *S. aureus*. In addition, resistance to methicillin is highly frequent in *S. epidermidis* isolations and less frequent amongst *S. aureus* isolations (over 70% of *S. epidermidis* hospital isolations are resistant to methicillin). Hence, it is possible for SCCmec diversity to be greater in *S. epidermidis*.^{31,33} In a study conducted by Wisplinghoff

et al., type IV SCCmec was highly frequent amongst *S. epidermidis* isolations during the seventies and was not found among MRSA isolations recovered during this time. However, the first *S. aureus* with type IV SCCmec was recovered during the eighties.³¹ Type V SCCmec is also distributed among CoNS.³⁴ The characterization of *S. haemolyticus* SCCmec has proven that type V SCCmec is the most frequent amongst this species, even though there have also been reports of other SCCmec structures.^{33,34}

Nosocomial frequency of methicillin-resistant *S. haemolyticus* may be as high as 90%,³⁵ while also being resistant to most antibiotics. As for *S. epidermidis*, from the association with type V SCCmec emerges the hypothesis of transference from said SCCmec type to *S. aureus*, which has been shown through SCCmec sequencing in both species, resulting in a homology superior to 99%, thus making the transference between species possible, which would involve *S. haemolyticus* as a reservoir of type V SCCmec.³⁵

The loss of ccr complex has been demonstrated in *S. haemolyticus*, which may contribute to the resistance phenotype providing *S. haemolyticus* the ability to retain the resistance to methicillin and resistance to other antimicrobial agents contained in SCCmec. Additionally, over 82 insertion sequences have been detected in *S. haemolyticus*, which are thought to provide a high genomic plasticity to the species.²⁹

It has been suggested that class C *mec* complex and *ccrC* complex were originated in *S. haemolyticus*; and that type V SCCmec and other SCCmec variants were generated in this specie. This hypothesis is frequently supported by the finding of 99% of nucleotide identity amongst class C *mec* complexes identified in MRSA and SH-MR isolations.^{29,35}

Barros et al.³⁴ reported 43% (24 isolations) of *S. haemolyticus* isolations as non-typeables. Therefore, it is clear that the diversity of elements in the *S. haemolyticus* genome is really large, thus the best way to know this diversity would be through their sequencing.

Conclusions

Resistance to methicillin (with the subsequent resistance to a variety of pharmaceuticals) is a worldwide distribution problem which occurs in community-related infections as well as in nosocomial infections. The increase in the frequency of infections caused by multi-resistant microorganisms makes the study of distribution and diversity of genetic elements which confer resistance to pharmaceuticals in bacteria of clinical importance necessary, as well as the study of transmission mechanisms of such elements.

Conflict of interest

The authors have no conflicts of interest to declare.

References

1. Garcia P. Coagulase-negative staphylococci: clinical, microbiological and molecular features to predict true bacteraemia. *J Med Microbiol.* 2004;53:67–72.
2. Tashiro M, Izumikawa K, Ashizawa N, et al. Clinical significance of methicillin-resistant coagulase-negative staphylococci obtained from sterile specimens. *Diagn Microbiol Infect Dis.* 2015;81:71–5.
3. Talebi M, Shafiee M, Sadeghi J, et al. Genotypic diversity of methicillin-resistant coagulase-negative staphylococci isolated from inpatients and outpatients. *Microb Drug Resist.* 2015;22.
4. Salas-Sánchez OA, Rivera-Morales I. Incidencia de infecciones relacionadas a catéteres venosos centrales (CVC) en la Unidad de Cuidados Intensivos (UCI) de un hospital universitario. *Med Univ.* 2010;12:91–5.
5. Rendón-Elías FG, Del Campo-Abadiano JA, Arrazolo-Ortega LS, et al. Surgical management of infective endocarditis: 10 years experience. *Med Univ.* 2012;14:196–204.
6. Ortega M, Marco F, Soriano A, et al. Epidemiology and outcome of bacteraemia in neutropenic patients in a single institution from 1991 to 2012. *Epidemiol Infect.* 2015;143:734–40.
7. John JF, Harvin AM. History and evolution of antibiotic resistance in coagulase-negative staphylococci: susceptibility profiles of new anti-staphylococcal agents. *Ther Clin Risk Manage.* 2007;3:1143–52.
8. Widerstrom M, Wistrom J, Sjostedt A, et al. Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on *Staphylococcus epidermidis* and *Staphylococcus saprophyticus*. *Eur J Clin Microbiol Infect Dis.* 2012;31:7–20.
9. Shorr AF. Epidemiology of staphylococcal resistance. *Clin Infect Dis.* 2007;45 Suppl. 3:S171–6.
10. Kristof K, Kocsis E, Szabo D, et al. Significance of methicillin-teicoplanin resistant *Staphylococcus haemolyticus* in bloodstream infections in patients of the Semmelweis University hospitals in Hungary. *Eur J Clin Microbiol Infect Dis.* 2011;30:691–9.
11. Mombach Pinheiro Machado AB, Reiter KC, Paiva RM, et al. Distribution of staphylococcal cassette chromosome *mec* (SCCMec) types I, II, III and IV in coagulase-negative staphylococci from patients attending a tertiary hospital in southern Brazil. *J Med Microbiol.* 2007;56 Pt 10:1328–33.
12. Miragaia M, Couto I, Pereira SFF, et al. Molecular characterization of methicillin-resistant *Staphylococcus epidermidis* clones: evidence of geographic dissemination. *J Clin Microbiol.* 2002;40:430–8.
13. Ibrahem S, Salmenlinna S, Virolainen A, et al. Carriage of methicillin-resistant Staphylococci and their SCCmec types in a long-term-care facility. *J Clin Microbiol.* 2009;47:32–7.
14. Jamaluddin TZ, Kuwahara-Arai K, Hisata K, et al. Extreme genetic diversity of methicillin-resistant *Staphylococcus epidermidis* strains disseminated among healthy Japanese children. *J Clin Microbiol.* 2008;46:3778–83.
15. Sauvage E, Kerff F, Terrak M, et al. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. *FEMS Microbiol Rev.* 2008;32:234–58.
16. Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and beta-lactam resistance. *FEMS Microbiol Rev.* 2008;32:361–85.
17. Peacock SJ, Paterson GK. Mechanisms of methicillin resistance in *Staphylococcus aureus*. *Annu Rev Biochem.* 2015;84:577–601.
18. Fishovitz J, Hermoso JA, Chang M, et al. Penicillin-binding protein 2a of methicillin-resistant *Staphylococcus aureus*. *IUBMB Life.* 2014;66:572–7.
19. International Working Group on the Classification of Staphylococcal Cassette Chromosome E. Classification of staphylococcal cassette chromosome *mec* (SCCMec): guidelines for reporting novel SCCmec elements. *Antimicrob Agents Chemother.* 2009;53:4961–7.
20. IWG-SCC. SCCmec Background. International Working Group on the Staphylococcal Cassette Chromosome elements; 2008. Available from: <http://www.sccmec.org/Pages/SCC-ClassificationEN.html>

21. Ito T, Ma XX, Takeuchi F, et al. Novel type V staphylococcal cassette chromosome *mec* driven by a novel cassette chromosome recombinase, *ccrC*. *Antimicrob Agents Chemother*. 2004;48:2637–51.
22. Zhang K, McClure JA, Elsayed S, et al. Novel staphylococcal cassette chromosome *mec* type, tentatively designated type VIII, harboring class A *mec* and type 4 *ccr* gene complexes in a Canadian epidemic strain of methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2009;53:531–40.
23. Berglund C, Ito T, Ikeda M, et al. Novel type of staphylococcal cassette chromosome *mec* in a methicillin-resistant *Staphylococcus aureus* strain isolated in Sweden. *Antimicrob Agents Chemother*. 2008;52:3512–6.
24. Oliveira DC, Milheirico C, de Lencastre H. Redefining a structural variant of staphylococcal cassette chromosome *mec*, SCCmec type VI. *Antimicrob Agents Chemother*. 2006;50:3457–9.
25. Shore AC, Deasy EC, Slickers P, et al. Detection of staphylococcal cassette chromosome *mec* type XI carrying highly divergent *mecA*, *mecI*, *mecR1*, *blaZ*, and *ccr* genes in human clinical isolates of clonal complex 130 methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2011;55:3765–73.
26. Cavanagh JP, Hjerde E, Holden MT, et al. Whole-genome sequencing reveals clonal expansion of multi-resistant *Staphylococcus haemolyticus* in European hospitals. *J Antimicrob Chemother*. 2014;69:2920–7.
27. Ito T, Katayama Y, Asada K, et al. Structural comparison of three types of staphylococcal cassette chromosome *mec* integrated in the chromosome in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2001;45:1323–36.
28. Hanssen AM, Kjeldsen G, Sollid JU. Local variants of Staphylococcal cassette chromosome *mec* in sporadic methicillin-resistant *Staphylococcus aureus* and methicillin-resistant coagulase-negative Staphylococci: evidence of horizontal gene transfer? *Antimicrob Agents Chemother*. 2004;48:285–96.
29. Bouchami O, Ben Hassen A, de Lencastre H, et al. High prevalence of *mec* complex C and *ccrC* is independent of SCCmec type V in *Staphylococcus haemolyticus*. *Eur J Clin Microbiol Infect Dis*. 2012;31:605–14.
30. Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant *Staphylococcus aureus* clones in the community. *J Clin Microbiol*. 2002;40:4289–94.
31. Wisplinghoff H, Rosato AE, Enright MC, et al. Related clones containing SCCmec type IV predominate among clinically significant *Staphylococcus epidermidis* isolates. *Antimicrob Agents Chemother*. 2003;47:3574–9.
32. Hanssen AM, Sollid JU. Multiple staphylococcal cassette chromosomes and allelic variants of cassette chromosome recombinases in *Staphylococcus aureus* and coagulase-negative staphylococci from Norway. *Antimicrob Agents Chemother*. 2007;51:1671–7.
33. Ruppe E, Barbier F, Mesli Y, et al. Diversity of staphylococcal cassette chromosome *mec* structures in methicillin-resistant *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* strains among outpatients from four countries. *Antimicrob Agents Chemother*. 2009;53:442–9.
34. Barros EM, Ceotto H, Bastos MC, et al. *Staphylococcus haemolyticus* as an important hospital pathogen and carrier of methicillin resistance genes. *J Clin Microbiol*. 2012;50:166–8.
35. Berglund C, Soderquist B. The origin of a methicillin-resistant *Staphylococcus aureus* isolate at a neonatal ward in Sweden—possible horizontal transfer of a staphylococcal cassette chromosome *mec* between methicillin-resistant *Staphylococcus haemolyticus* and *Staphylococcus aureus*. *Clin Microbiol Infect*. 2008;14:1048–56.